These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 26084446)

  • 1. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes.
    Sarao V; Veritti D; Macor S; Lanzetta P
    Graefes Arch Clin Exp Ophthalmol; 2016 Mar; 254(3):445-54. PubMed ID: 26084446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
    Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F; Hamasaki T; Tano Y
    Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS; Kim JG; Kim JT; Joe SG
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
    Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
    Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Sheth S; Bandello F
    Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
    Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
    Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F
    Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
    Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
    Retina; 2007; 27(6):707-12. PubMed ID: 17621179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results.
    Peiretti E; Vinci M; Fossarello M
    Can J Ophthalmol; 2012 Feb; 47(1):28-33. PubMed ID: 22333848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
    Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
    Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
    Kung YH; Wu TT; Huang YH
    Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China : Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization.
    Nie X; Wang Y; Yi H; Qiao Y
    BMC Ophthalmol; 2021 Mar; 21(1):116. PubMed ID: 33663431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia.
    Rhéaume MA; Sebag M
    Can J Ophthalmol; 2008 Oct; 43(5):576-80. PubMed ID: 18982035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
    Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.